About Altis Biosystems
Altis Biosystems is a company based in Durham (United States) founded in 2015 by Scott Magness, Nancy Allbritton, Michael Biron, Yuli Wang, and Christopher Sims.. Altis Biosystems has raised $7.53 million across 15 funding rounds from investors including HHS, NCBiotech and Atlanta Technology Angels. Altis Biosystems offers products and services including RepliGut® Kits, Custom InflammaScreen, and StemTox. Altis Biosystems operates in a competitive market with competitors including Toxys, ATANIS Biotech, Inovotion, ABL Diagnostics and BioTalentum, among others.
- Headquarter Durham, United States
- Founders Scott Magness, Nancy Allbritton, Michael Biron, Yuli Wang, Christopher Sims
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Altis Biosystems, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$7.53 M (USD)
in 15 rounds
-
Latest Funding Round
$2.13 M (USD), Seed
Mar 31, 2025
-
Investors
HHS
& 7 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Altis Biosystems
Altis Biosystems offers a comprehensive portfolio of products and services, including RepliGut® Kits, Custom InflammaScreen, and StemTox. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Kits for replicating human intestinal structures in drug testing.
Service to evaluate inflammatory effects on intestinal models.
Assay for predicting gastrointestinal toxicity risks in therapeutics.
Unlock access to complete
Unlock access to complete
Funding Insights of Altis Biosystems
Altis Biosystems has successfully raised a total of $7.53M across 15 strategic funding rounds. The most recent funding activity was a Seed round of $2.13 million completed in March 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 15
- Last Round Seed — $2.1M
- First Round First Round
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2025 | Amount | Seed - Altis Biosystems | Valuation |
investors |
|
| Sep, 2023 | Amount | Grant - Altis Biosystems | Valuation |
investors |
|
| Jul, 2023 | Amount | Grant - Altis Biosystems | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Altis Biosystems
Altis Biosystems has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, NCBiotech and Atlanta Technology Angels. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Biotech startups are incubated and funded in North Carolina.
|
Founded Year | Domain | Location | |
|
Early-stage ventures in the Southeast are supported by VentureSouth.
|
Founded Year | Domain | Location | |
|
Angel investments are provided across Atlanta and Georgia.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Altis Biosystems
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Altis Biosystems
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Altis Biosystems Comparisons
Competitors of Altis Biosystems
Altis Biosystems operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Toxys, ATANIS Biotech, Inovotion, ABL Diagnostics and BioTalentum, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
In vitro genotoxicity testing services are provided using proprietary technology.
|
|
| domain | founded_year | HQ Location |
Developer of a cell-based assay for the diagnosis of allergies
|
|
| domain | founded_year | HQ Location |
Provider of in vivo oncology efficacy and toxicity assays for drug discovery and development
|
|
| domain | founded_year | HQ Location |
Molecular biology assays and kits are developed for microbiology labs.
|
|
| domain | founded_year | HQ Location |
Human stem-cell technologies for drug testing and toxicology are provided.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Altis Biosystems
Frequently Asked Questions about Altis Biosystems
When was Altis Biosystems founded?
Altis Biosystems was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Where is Altis Biosystems located?
Altis Biosystems is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
Who is the current CEO of Altis Biosystems?
Michael Biron is the current CEO of Altis Biosystems. They have also founded this company.
Is Altis Biosystems a funded company?
Altis Biosystems is a funded company, having raised a total of $7.53M across 15 funding rounds to date. The company's 1st funding round was a Grant of $1.83M, raised on Nov 20, 2017.
What does Altis Biosystems do?
Altis Biosystems was founded in 2015 in Durham, United States, focusing on biotechnology for drug development. A stem cell-derived platform called RepliGut is utilized to assess drug disposition, including toxicity, metabolism, absorption, and efficacy. Operations center on in vitro modeling to support pharmaceutical research, with services aimed at improving drug safety and performance evaluations.
Who are the top competitors of Altis Biosystems?
Altis Biosystems's top competitors include ABL Diagnostics, ATANIS Biotech and Toxys.
What products or services does Altis Biosystems offer?
Altis Biosystems offers RepliGut® Kits, Custom InflammaScreen, and StemTox.
Who are Altis Biosystems's investors?
Altis Biosystems has 8 investors. Key investors include HHS, NCBiotech, Atlanta Technology Angels, VentureSouth, and Central Texas Angel Network.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.